Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you consider switching capmatinib to tepotinib or vice versa due to grade 3 hepatotoxicity in a patient with metastatic NSCLC with MET Exon 14 skipping mutation?
Related Questions
Do you perform EBUS-TBNA for staging in patients with biopsy proven malignant lung nodules with no lymphadenopathy on CT chest and PET scan?
Would you treat a completely resected Stage IA NSCLC EGFR exon 19 with adjuvant osimertinib alone omitting chemotherapy?
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
How would you manage a patient with stage IV EGFR L858R mutation but with a debilitating drug rash from osimertinib?
Do you perform routine interval lung cancer screening in non-smokers who are 1st degree relatives of patients with non-smoking related lung cancers with known EGFR mutations?
At what age do you stop LDCT chest for lung cancer screening?
Is there a role for surgical debulking for patients with stage IV lung sarcomatoid carcinoma?
How would you approach local therapy (surgery or RT) in a patient with radiographic complete response after chemoimmunotherapy for non-small-cell lung cancer?
What is your approach to obtain tissue diagnosis for a patient with a lung primary and spine metastasis?
Would you offer consolidative radiotherapy for oligometastatic NSCLC?
